SPIE SA

SPIE announced it has acquired 94% of CLAUSER, a family-owned French company specializing in industrial maintenance and high-power electrical installations. Founded in 1963 and based in Saint-Jean-de-Maurienne and Dunkirk, CLAUSER employs around 100 people and generated revenue of approximately €22 million in 2025. The company is recognized for its longstanding expertise in aluminium production and processing as well as electrochemical processes. SPIE said the deal strengthens its position in industrial maintenance and high-power electrical installations, a sector where the electrification of industrial processes is playing an increasingly important role. Frédéric Toussaint, Managing Director of SPIE Industrie (France), said CLAUSER's expertise in aluminium-related processes is a major asset for supporting the electrification and decarbonisation of French industrial sites.

SPIE has issued a €500 million sustainability-linked bond tied to its environmental and social commitments, with a 5.5 year term and a 4.875% coupon. The group plans an early redemption of its 2028 ORNANEs, reshaping its debt profile ahead of the original maturity and shifting obligations out to 2030. Proceeds from the new bond are expected to support SPIE's energy, digital and industrial transition projects. The key proof point to watch is how net debt evolves by the October 22, 2026 early redemption date for the remaining ORNANEs, including whether SPIE uses operating cash flow to bring leverage down rather than simply rolling obligations into fresh borrowings. SPIE, a €7.6b Commercial Services group headquartered in GB, focuses on multi-technical services that keep energy and communications infrastructure running in France, Germany, the Netherlands and other markets.

SPIE has acquired nimeg ag, a Swiss engineering service provider specializing in the life sciences industry. nimeg ag, based in Baden-Dättwil, focuses on engineering, planning, and project management in GMP environments for EPCMV projects, serving clients in pharma, chemicals, biotech, and medical technology. The company generated revenues of approximately €5 million in 2025. SPIE says the deal strengthens its position in the growing pharmaceutical and biotechnology facilities market and expands its industrial services offering in Switzerland.